Back to today’s briefing

Story perspectives

FDA Fast-Tracks Psilocybin for Depression Amid Legal Shift

1/17/2026

33 6

Summary

Story summary

The FDA plans to expedite a psilocybin treatment's review for severe depression, aiming for approval by year-end.
This marks a shift in the administration of U.S. President Donald Trump toward psychedelic therapies.
States such as New Mexico, Colorado, and Oregon are offering legal psilocybin therapy, while others consider easing restrictions.
Oregon's program faces high costs and staffing issues, with about one-third of licensed centers closing.

1 of 1

Story summary

The FDA plans to expedite a psilocybin treatment's review for severe depression, aiming for approval by year-end.
This marks a shift in the administration of U.S. President Donald Trump toward psychedelic therapies.
States such as New Mexico, Colorado, and Oregon are offering legal psilocybin therapy, while others consider easing restrictions.
Oregon's program faces high costs and staffing issues, with about one-third of licensed centers closing.